Kannalife, Inc. Announces Completion of NIH-NIDA Phase 1 Grant and Results from Lewis Katz School of Medicine at Temple University for the Potential Use of KLS-13019 in the Treatment of CIPN


You May Also Like

Oncobiologics Closes on Final Portion of $15 Million Senior Secured Note and Warrant Offering

CRANBURY, N.J., June 01, 2017 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical ...